以色列 - 英文 - Ministry of Health

glaxo smith kline (israel) ltd - fluticasone propionate; salmeterol as xinafoate - powder for inhalation - fluticasone propionate 500 mcg; salmeterol as xinafoate 50 mcg - salmeterol and other drugs for obstructive airway diseases - seretide is indicated in the regular treatment of asthma in children and adults, where use of a combination (bronchodilator and inhaled corticosteroid) has been found to be appropriate. seretide (50/500 mcg) is indicated for the symptomatic treatment of patients with copd, with a fev1 <60% predicted normal (pre-bronchodilator) and a history of repeated exacerbations, who have significant symptoms despite regular bronchodilator therapy.

马耳他 - 英文 - Malta Medicines Authority

sanofi malta limited level2, fort business centre, mriehel bypass, birkirkara, malta - salmeterol, fluticasone propionate - inhalation powder - salmeterol 50 µg fluticasone propionate 500 µg - drugs for obstructive airway diseases

马耳他 - 英文 - Malta Medicines Authority

glaxo smithkline ireland limited 12, riverwalk, citywest business campus, dublin 24, ireland - salmeterol - pressurised inhalation, suspension - salmeterol 25 µg - drugs for obstructive airway diseases

欧盟 - 英文 - EMA (European Medicines Agency)

astrazeneca ab - roflumilast - pulmonary disease, chronic obstructive - drugs for obstructive airway diseases, - daliresp is indicated for maintenance treatment of severe chronic obstructive pulmonary disease (copd) (fev1 post-bronchodilator less than 50% predicted) associated with chronic bronchitis in adult patients with a history of frequent exacerbations as add-on to bronchodilator treatment.

欧盟 - 英文 - EMA (European Medicines Agency)

astrazeneca ab - roflumilast - pulmonary disease, chronic obstructive - drugs for obstructive airway diseases, - daxas is indicated for maintenance treatment of severe chronic obstructive pulmonary disease (copd) (fev1 post-bronchodilator less than 50% predicted) associated with chronic bronchitis in adult patients with a history of frequent exacerbations as add-on to bronchodilator treatment.,

欧盟 - 英文 - EMA (European Medicines Agency)

novartis europharm limited - indacaterol maleate - pulmonary disease, chronic obstructive - drugs for obstructive airway diseases, - hirobriz breezhaler is indicated for maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease.

欧盟 - 英文 - EMA (European Medicines Agency)

astrazeneca ab - roflumilast - pulmonary disease, chronic obstructive - drugs for obstructive airway diseases, - libertek is indicated for maintenance treatment of severe chronic obstructive pulmonary disease (copd) (fev1 post-bronchodilator less than 50% predicted) associated with chronic bronchitis in adult patients with a history of frequent exacerbations as add-on to bronchodilator treatment.

欧盟 - 英文 - EMA (European Medicines Agency)

novartis europharm limited  - indacaterol maleate - pulmonary disease, chronic obstructive - drugs for obstructive airway diseases, - oslif breezhaler is indicated for maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease.

欧盟 - 英文 - EMA (European Medicines Agency)

novartis europharm limited - glycopyrronium bromide, indacaterol maleate - pulmonary disease, chronic obstructive - drugs for obstructive airway diseases, - ulunar breezhaler is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (copd).

欧盟 - 英文 - EMA (European Medicines Agency)

novartis europharm limited  - indacaterol maleate - pulmonary disease, chronic obstructive - drugs for obstructive airway diseases, - onbrez breezhaler is indicated for maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease.